logo
AI Icon𝛼SK or Search
ENTITY

Leads Biolabs (9887 HK)

56
Analysis
Health Care • China
Leads Biolabs is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies for oncology, autoimmune, and other severe diseases, focusing on unmet medical needs. The company leverages proprietary technology platforms to advance a pipeline of drug candidates, including bispecific antibodies and fusion proteins. Founded in 2012, Leads Biolabs is headquartered in Nanjing, China.
more
Exchange Announcement • 12 Oct 2026 06:04

Voluntary Announcement Lbl-024 (Opamtistomig, Pd-L1/4-1bb Bispecific Antibody) Granted Fast Track Designation By The U.S. Fda For First-Line Treatment Of Advanced Biliary Tract Cancer

Exchange Announcement • 28 Sep 2026 12:13

Voluntary Announcement Lbl-024 (Opamtistomig, Pd-L1/4-1bb Bispecific Antibody) Granted Orphan Drug Designation In Japan

Exchange Announcement • 23 Sep 2026 21:47

2026 Interim Report

Exchange Announcement • 21 Sep 2026 22:12

Voluntary Announcement Pivotal Registrational Phase Iib Study Of Lbl-024 (Opamtistomig, Pd-L1/4-1bb Bispecific Antibody) Monotherapy In Advanced Ep-Nec Selected As Lba And Three Studies Selected For Proffered Paper Presentations At 2026 Esmo

Exchange Announcement • 14 Sep 2026 17:10

Voluntary Announcement Updated Data From Phase Ii Clinical Study Of Lbl-024 (Opamtistomig, Pd-L1/4-1bb Bispecific Antibody) In Combination With Chemotherapy As First-Line Treatment For Nsclc Presented Orally At Wclc 2026

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4

x